Mexico- Results of sensitivity analysis on average cost-effectiveness ratio (ACER).

a<p>Unidad de Análisis Económico - 8.4% stage I, 38.5% stage II, 42.5% stage III, 10.6% stage IV <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0095836#pone.0095836-Comisin1" target="_blank">[42]</a>.</p>b<p>9.7% stage I, 52.7% stage II, 34.8% stage III, 2.8% stage IV <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0095836#pone.0095836-FloresLuna1" target="_blank">[41]</a>.</p>c<p>9.4% stage I, 14.2% stage II, 58.0% stage III, 18.4% stage IV <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0095836#pone.0095836-Groot1" target="_blank">[7]</a>.</p>d<p>Alternative Case Fatality rates: 0,013 stage I, 0,042 stage II, 0,102 stage III, 0,266 stage IV <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0095836#pone.0095836-Salomon1" target="_blank">[35]</a>.</p>e<p>Mechanical equipment (e.g. mammography machines, CT, X-ray).</p>f<p>Alternative assumptions on effectiveness of awareness interventions (−25%), sensitivity of CBE, and stage shifts of CBE screening.